| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
NCT-14b targets histone deacetylase 6 (HDAC6), a class IIb histone deacetylase that deacetylates α-tubulin, cortactin, and other non-histone substrates. HDAC6 is involved in various cellular processes including cell motility, protein degradation, and aggresome formation. By selectively inhibiting HDAC6, NCT-14b increases acetylation of α-tubulin and other HDAC6 substrates, affecting microtubule dynamics and cellular signaling. The compound shows high selectivity for HDAC6 over other HDAC isoforms.
|
|---|---|
| ln Vitro |
In vitro, NCT-14b potently inhibits HDAC6 with an IC₅₀ of 84 nM. It shows >40-fold selectivity over other HDAC isoforms (IC₅₀ >3.5 μM). The compound inhibits cell growth of estrogen receptor α-positive MCF-7 breast cancer cells treated with estrogen but not untreated cells. This suggests estrogen-dependent activity. Detailed in vitro data are available in the primary literature. The compound is a valuable tool for studying HDAC6-selective inhibition.
|
| ln Vivo |
In vivo data for NCT-14b are limited in publicly available sources. Based on its potent in vitro activity and selectivity for HDAC6, the compound is expected to be useful for in vivo studies of HDAC6 function in cancer and other diseases. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile. The compound is a research tool for epigenetic studies.
|
| Enzyme Assay |
In vitro HDAC activity assays for NCT-14b typically use recombinant HDAC6 enzyme or HeLa nuclear extracts with fluorogenic substrate (e.g., Boc-Lys(Ac)-AMC). The compound is dissolved in DMSO and diluted in assay buffer (50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂). Reactions are incubated at 37°C for 30-60 minutes and terminated by adding developer (trypsin and TSA). Fluorescence (excitation 360 nm, emission 460 nm) is measured. IC₅₀ values are calculated from dose-response curves. Selectivity is assessed against other HDAC isoforms using similar assays with isoform-specific substrates.
|
| Cell Assay |
For cell-based assays, MCF-7 breast cancer cells are cultured in DMEM with 10% FBS and estrogen supplementation. Cells are seeded in 96-well plates and treated with NCT-14b at various concentrations (0.01-10 μM) for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo. α-Tubulin acetylation is measured by Western blotting to confirm HDAC6 inhibition. Cell cycle analysis is performed by flow cytometry. Gene expression changes are analyzed by RT-PCR. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NCT-14b may be administered to rodents via intraperitoneal (IP) or intravenous (IV) injection. The compound is formulated in a suitable vehicle such as DMSO, PEG, or saline-based solutions. For tumor xenograft models, immunodeficient mice bearing MCF-7 tumors are dosed at various regimens. Endpoints include tumor volume measurement, survival analysis, and biomarker assessment (α-tubulin acetylation in tumor tissues). Blood and tissue samples are collected for pharmacokinetic and pharmacodynamic analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
NCT-14b (MW ~460, C₂₆H₄₄N₂O₄S) is soluble in DMSO. The compound is a selective HDAC6 inhibitor with an IC₅₀ of 84 nM. Detailed pharmacokinetic parameters (bioavailability, half-life, clearance) are not extensively reported in publicly available sources. The compound is typically stored at -20°C. Further ADME studies are needed to fully characterize its pharmacokinetic profile.
|
| Toxicity/Toxicokinetics |
Toxicology data for NCT-14b are limited in publicly available sources. As an HDAC inhibitor, potential off-target effects on other HDAC isoforms and cellular processes should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
NCT-14b (TCS HDAC6 20b) is a research-grade chemical probe for studying HDAC6 function in cancer and other diseases. Its primary applications include cancer research, epigenetics, and drug discovery. The compound is not approved for clinical use and has not entered clinical trials. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves selective inhibition of HDAC6, affecting microtubule dynamics, cell motility, and protein degradation pathways.
|
| Molecular Formula |
C26H44N2O4S
|
|---|---|
| Molecular Weight |
480.71
|
| Exact Mass |
480.302
|
| Elemental Analysis |
C, 64.96; H, 9.23; N, 5.83; O, 13.31; S, 6.67
|
| CAS # |
956154-63-5
|
| PubChem CID |
23636017
|
| Appearance |
Solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
631.3±55.0 °C at 760 mmHg
|
| Flash Point |
335.6±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.537
|
| LogP |
5.66
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
33
|
| Complexity |
674
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C(C(C)C)=O)CCCCC[C@@H](C(NC12CC3CC(CC(C3)C1)C2)=O)NC(=O)OC(C)(C)C
|
| InChi Key |
DQZMLPMCOMRJOR-MOVGKWKRSA-N
|
| InChi Code |
InChI=1S/C26H44N2O4S/c1-17(2)23(30)33-10-8-6-7-9-21(27-24(31)32-25(3,4)5)22(29)28-26-14-18-11-19(15-26)13-20(12-18)16-26/h17-21H,6-16H2,1-5H3,(H,27,31)(H,28,29)/t18?,19?,20?,21-,26?/m0/s1
|
| Chemical Name |
S-[(6S)-7-(1-adamantylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]-7-oxoheptyl] 2-methylpropanethioate
|
| Synonyms |
NCT14b; NCT 14b; NCT-14b; TCS-HDAC6; NCT14-b; TCS HDAC6
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0803 mL | 10.4013 mL | 20.8026 mL | |
| 5 mM | 0.4161 mL | 2.0803 mL | 4.1605 mL | |
| 10 mM | 0.2080 mL | 1.0401 mL | 2.0803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
